A5026442898- Influenza Virus Research Studies
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Herpesvirus Infections and Treatments
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Virology and Viral Diseases
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Viral Infections and Immunology Research
- COVID-19 and Mental Health
- Poxvirus research and outbreaks
- Animal Disease Management and Epidemiology
- Zoonotic diseases and public health
- Bacillus and Francisella bacterial research
- Hepatitis Viruses Studies and Epidemiology
- Neonatal Respiratory Health Research
- Animal Virus Infections Studies
- Viral Infections and Vectors
- Infection Control and Ventilation
- Nosocomial Infections in ICU
- Immunodeficiency and Autoimmune Disorders
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
Instituto de Salud Pública de Navarra
2014-2025
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2014-2025
Navarre Institute of Health Research
2016-2024
Instituto de Salud Carlos III
2012-2024
Agència de Salut Pública de Catalunya
2013-2024
Departamento de Salud
2023
Gobierno de Navarra
2023
Public Health Institute
2009-2023
Biomedical Research Institute of Lleida
2020
Universidad Publica de Navarra
2016-2017
Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months life; however, this risk rapidly decreases with age. Nirsevimab immunoprophylaxis was approved European Union for prevention RSV-associated lower respiratory tract disease infants during their RSV season. We evaluated effectiveness nirsevimab preventing hospitalisations confirmed and impact strategy immunisation at birth. A population-based cohort study performed Navarre, Spain, where...
BackgroundRespiratory syncytial virus (RSV) causes substantial morbidity in infants < 1 year. In October 2023, Spain recommended the monoclonal antibody nirsevimab to all children born since April at birth or as catch-up if before 2023.AimWe estimated effectiveness preventing RSV hospitalisations during 2023/24 season.MethodsWe conducted a nationwide population-based matched case-control study. Cases were hospitalised for lower respiratory tract infection who PCR-positive. For each case, we...
Binary file ES_Abstracts_Final_ECDC.txt matches
During June 2022, Spain was one of the countries most affected worldwide by a multicountry monkeypox outbreak with chains transmission without identified links to disease-endemic countries. We provide epidemiologic features cases reported in and coordinated measures taken respond this outbreak.
In September 2015, the four-component, protein-based meningococcal serogroup B vaccine (4CMenB; Bexsero) became available for private purchase in Spain.We conducted a nationwide matched case-control study to assess effectiveness of 4CMenB preventing invasive disease children. The included all laboratory-confirmed cases children younger than 60 months age between October 5, and 6, 2019, Spain. Each case patient was with four controls according date birth province. vaccination status patients...
With more than 7500 cases reported since April 2022, Spain has experienced the highest incidence of mpox in Europe. From 12 July onward, modified vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for those receiving human immunodeficiency virus (HIV-PrEP). Our aim to assess effectiveness 1 dose MVA-BN against (MPXV) infection persons on HIV-PrEP.
COVID-19 vaccination was expected to reduce SARS-CoV-2 transmission, but the relevance of this effect remains unclear. We aimed estimate effectiveness index cases and their close contacts in reducing probability transmission.Transmission infection evaluated two cohorts adult confirmed (social household settings) by status case contact, from April November 2021 Navarre, Spain. The effects contact were estimated as (1-adjusted relative risk) × 100%.Among 19,631 social contacts, 3257 (17%) with...
In 2007 in Navarre, Spain, universal varicella vaccination with two doses of Varivax was introduced the childhood immunisation schedule for children aged 15 months and three years. This study describes changes epidemiology period 2006 to 2012 evaluates effectiveness using epidemiological surveillance data. The incidence 0 14 years decreased by 98.1%, from 50.1 cases per 1,000 inhabitants 2006, 1.0 2012. Children one eight were vaccinated cohorts, their 98.5% (p<0.0001). unvaccinated age...
In Spain, the influenza vaccine effectiveness (VE) was estimated in last three seasons using observational study cycEVA conducted frame of existing Spanish Influenza Sentinel Surveillance System. The objective to estimate against medically attended, laboratory-confirmed influenza-like illness (ILI) among target groups for vaccination Spain 2011–2012 season. We also studied VE early (weeks 52/2011-7/2012) and late 8-14/2012) phases epidemic according time since vaccination. Medically attended...
PERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended vaccination pregnancy. Among infants aged <2 months, we measured vaccine effectiveness (VE) pregnancy; among 2–11 VE pregnancy and primary (PV). From December 2015 to included all <1 year presenting with pertussis-like symptoms. Using a test-negative-design, cases were testing positive Bordetella by PCR or culture. Controls those negative...
Importance In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) inform vaccination campaigns. Objective To estimate vaccines administered in autumn winter 2022 2023 against symptomatic infection (with all circulating viruses XBB lineage particular) among people aged 60 years older Europe, compare different CVE approaches across exposed reference groups used. Design, Setting, Participants This...
Varicella vaccine effectiveness was evaluated in a case-control study Navarre, Spain, 2010–2012. The cases were 54 children aged 15 months to 10 years with diagnosis of varicella confirmed by polymerase-chain-reaction. Each case matched eight controls pediatric practice, district residence and date birth. 87% (95% confidence interval: 60% 97%) for one dose 97% (80% 100%) two doses. A single 93% (34% effective the first year, which declined 61% CI: -64% 94%) after third year. In conclusion,...
Some studies have evaluated vaccine effectiveness in preventing outpatient influenza while others analysed its hospitalizations. This study evaluates the of trivalent illness and hospitalizations from laboratory-confirmed 2010–2011 season. We conducted a nested case–control population covered by general practitioner sentinel network for surveillance Navarre, Spain. Patients with influenza-like hospitals primary health care were swabbed testing. Influenza vaccination status other covariates...
We present early estimates of influenza vaccine effectiveness (VE) in the population targeted for vaccination, during 25 December 2011 to 19 February 2012. The adjusted VE was 55% (95% CI: 3 79) against any type virus and 54% 1 A(H3N2) virus. This suggests a moderate protective effect late epidemic with limited match between circulating strains.
Acute flaccid paralysis (AFP) surveillance is key for global polio eradication. It allows detecting poliovirus (PV) reintroductions from endemic countries. This study describes AFP in Spain 1998 to 2015. During this time, 678 cases were reported the Spanish National Surveillance Network. The mean notification rate was 0.58 cases/100,000 population under 15 years old (range: 0.45/100,000-0.78/100,000). Two periods (P) are described: P1 (1998-2006) with ranging 0.66/100,000 0.78/100,000,...
SUMMARY An outbreak of Legionnaire's disease was detected in Pamplona, Spain, on 1 June 2006. Patients with pneumonia were tested to detect Legionella pneumophila antigen urine (Binax Now; Binax Inc., Scarborough, ME, USA), and all 146 confirmed cases interviewed. The related district 2 (22 012 inhabitants), where 45% the lived 50% had visited; 5% neighbouring districts. highest incidence found resident population (3/1000 section (14/1000). All 31 cooling towers analysed. L. Now) four...
We defined a cohort of people with major chronic conditions (152,585 subjects) in Navarre, Spain, using electronic records from physicians, to obtain 2010/11 mid-season estimates influenza vaccine effectiveness. The adjusted the effectiveness trivalent were 31% (95% confidence interval (CI): 20–40%) preventing medically attended influenza-like illness, and 58% CI: 11–80%) laboratory-confirmed influenza. Having received monovalent A(H1N1)2009 2009/10 season had an independent preventive...
We present estimates of influenza vaccine effectiveness (VE) in Navarre, Spain, the early 2012/13 season, which was dominated by B. In a population-based cohort using electronic records from physicians, adjusted VE preventing influenzalike illness 32% (95% confidence interval (CI): 15 to 46). nested test-negative case-control analysis laboratory-confirmed 86% CI: 45 96). These results suggest high protective effect vaccine.
La varicela es una enfermedad aguda muy contagiosa producida por el virus varicela-zoster, que deja inmunidad duradera.El herpes zóster se produce reactivación de infección latente mismo virus.La introducción la vacunación sistemática y gratuita frente a en niños 15 meses Navarra desde 2007, previsiblemente producirá cambios epidemiológicos importantes.Por ello, describimos situación epidemiológica